Short answer: not in the way the word suggests. BPC-157 is a research-use-only compound, not a scheduled or criminalised substance. In 2023 the FDA’s compounding review kept BPC-157 off the 503A Bulks List for human-use compounding — the decision behind most “BPC-157 banned” headlines. It remains available as a laboratory reagent, it returns for FDA advisory committee discussion in July 2026, and it is separately prohibited in tested sport by WADA.
“Is BPC-157 banned?” is a question shaped almost entirely by headlines, and the headlines compress a lot of nuance into one scary word. The accurate picture is more specific: BPC-157 was never approved as a medicine, a 2023 FDA decision limited its use in pharmacy compounding, and it sits in a research-use-only category today. Here is what actually happened.
First, the most common misunderstanding: BPC-157 is not a scheduled drug like a narcotic. There is no blanket criminal “ban” on the molecule itself. It is supplied to laboratories as a research reagent, labelled research use only, not for human consumption. As with most research compounds, the legal line is determined by how it is marketed and used — selling or labelling it for human use is what creates regulatory exposure — not by mere possession of a labelled reagent. Our explainer on whether peptides are legal sets out that distinction.
The source of most “BPC-157 banned” coverage is the FDA’s 2023 evaluation of substances nominated for use in pharmacy compounding. In that review, BPC-157 was not placed on the 503A Bulks List for human-use compounding; the agency raised concerns including limited safety characterisation and immunogenicity questions. In practice, that kept compounding pharmacies from preparing BPC-157 for people.
What “kept off the bulks list” means. It is a restriction on compounding for human use, not a criminalisation of the molecule. It actually reinforces the research-use-only category rather than contradicting it. We cover the decision in depth in our 2023 FDA peptide compounding explainer.
The story did not end in 2023. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee is scheduled to discuss BPC-157 bulk drug substances again (free base and acetate), with ulcerative colitis listed as the evaluated use, as part of a fresh review of several peptide-related substances for potential 503A Bulks List consideration.
Importantly, this is still a compounding review, not a drug-approval decision and not a reversal of a criminal ban (there was none). Whatever the committee recommends, it would not by itself make BPC-157 an FDA-approved medicine. The full agenda is covered in our FDA peptide review 2026 overview, and the regenerative angle in our BPC-157 and TB-500 review.
Here the word “banned” is accurate. The World Anti-Doping Agency (WADA) prohibits BPC-157 at all times under category S0 (non-approved substances) of its Prohibited List. Any athlete in a tested sport who uses it risks an anti-doping violation and sanctions, independent of the compound’s research-use status. If you compete under WADA or a national anti-doping code, treat BPC-157 as prohibited.
Much of the confusion comes from blurring two separate ideas:
None of those is the same as a blanket criminal ban, and conflating them is exactly how “is BPC-157 banned?” turns into misinformation.
Treat BPC-157 as what it is: a research compound with an unsettled regulatory status and an active FDA review. Responsible suppliers position it for laboratory research use only, not for human consumption, and back it with a Certificate of Analysis. Be sceptical of any seller claiming BPC-157 is “FDA approved,” “unbanned,” or “cleared for human use” on the back of the 2026 meeting — none of those claims would be accurate.
Is BPC-157 banned?
Not as a scheduled/illegal substance. It is research-use-only; the FDA’s 2023 review kept it off the 503A Bulks List for human-use compounding, and WADA bans it in sport.
Did the FDA ban BPC-157 in 2023?
The FDA kept it off the compounding bulks list for human use — a restriction on compounding, not a criminalisation of the molecule.
Could the July 2026 meeting “unban” it?
It is a compounding-list review, not a criminal matter. Any recommendation would not make BPC-157 an approved medicine.
Source: the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting agenda, and the WADA Prohibited List (category S0). External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalogAt New-U, we believe better conversations start with better information. For laboratory research use only. Not for human consumption.